CepTor Deal With Ferring For Infant Respiratory Drug Is Contingent Upon FDA Agreement On Phase II Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
After CepTor purchases superoxide dismutase from Ferring, the firm will repeat a Phase IIb study using new endpoints.
You may also be interested in...
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 1 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.